Inomax
Hemorrhagic Stroke
Cristália Produtos Químicos Farmacêuticos Ltda.Phase 4 / ApprovedDormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the Hemorrhagic Stroke cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cerebrolysin Cardinal Stefan Wyszynski University | Phase 4 | BB |
Lipitor Duan Chuanzhi | Phase 4 | BB |
Esmolol Cristália Produtos Químicos Farmacêuticos Ltda. | Phase 4 | BB |
compound solution of sodium chloride University Hospital Heidelberg | Phase 2 | B |
DEXKETOPROFEN Beijing Tiantan Hospital | Phase 2/3 | B |
View all 21 →
Same molecule, other indications
Inomax is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →